Shanghai-based ZAI Lab in-licenses autoimmune candidate from UCB

Shanghai-based biotech ZAI Lab has in-licensed global rights to a first-in-class monoclonal antibody aimed at treating autoimmune and other inflammatory diseases from Belgium's UCB, the company said in a press release. ZAI Lab said the candidate is deemed ready for Investigational New Drug-enabling studies and is expected to enter clinical Phase I in 2016. Initial indications are aimed at graft-versus-host disease and inflammatory bowel disease, ZAI Lab CEO Samantha Du said in the statement. Story

Suggested Articles

Bayer's finerenone beat placebo at slowing kidney disease and cut the risk of heart attacks and strokes in diabetic kidney disease patients.

The National Institute of Allergy and Infectious Diseases is launching a new clinical trials network for COVID-19.

While Sanofi is looking to move more of its R&D in-house, there is still room for deals, and today it’s penned a big one with Fierce 15 winner Kymera